Yes rikki, a truly remarkable result for Cantrixil and a way forward for the many women who suffer from this terrible cancer.
A complete recovery with one patient is validation of the science and hard work from Novogen and Yale scientists and researchers.
Associate Professor Jermaine Coward is a very caring and dedicated lead investigator responsible for our trial.
The upcoming Kazia SPP will be well supported and most likely over subscibed by the retail shareholders @ $0.40 per share.
Regards.
- Forums
- ASX - By Stock
- KZA
- Ann: Cantrixil last patient visit
Ann: Cantrixil last patient visit, page-12
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online